Growth Metrics

Merck (MRK) FCF Payout Ratio Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Cover Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -18.69%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 20.26%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 9.35%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -49.49%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -16.50%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -10.25%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -67.11%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 56.25%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -49.49%
Dec 31, 2025 27.53%
Sep 30, 2025 -8.69%
Jun 30, 2025 13.76%
Mar 31, 2025 55.86%
Dec 31, 2024 22.47%
Sep 30, 2024 -20.39%
Jun 30, 2024 -37.35%
Mar 31, 2024 -56.20%
Dec 31, 2023 -73.24%
Sep 30, 2023 -39.13%
Jun 30, 2023 -16.15%
Mar 31, 2023 44.29%
Dec 31, 2022 32.04%
Sep 30, 2022 -2.93%
Jun 30, 2022 -4.36%
Mar 31, 2022 -37.88%
Dec 31, 2021 -4.12%
Sep 30, 2021 -8.84%
Jun 30, 2021 52.66%
Mar 31, 2021 78.11%
Dec 31, 2020 26.13%
Sep 30, 2020 52.07%
Jun 30, 2020 37.71%
Mar 31, 2020 38.94%
Dec 31, 2019 -84.54%
Sep 30, 2019 -4.97%
Jun 30, 2019 -15.61%
Mar 31, 2019 41.84%
Dec 31, 2018 12.53%
Sep 30, 2018 12.24%
Jun 30, 2018 -4.44%
Mar 31, 2018 44.15%
Dec 31, 2017 35.18%
Sep 30, 2017 -65.11%
Jun 30, 2017 -12.41%
Mar 31, 2017 -249.81%
Dec 31, 2016 -5.26%
Sep 30, 2016 12.39%
Jun 30, 2016 15.32%
Mar 31, 2016 0.96%
Dec 31, 2015 27.92%
Sep 30, 2015 -3.23%
Jun 30, 2015 1.43%
Mar 31, 2015 -4.29%
Dec 31, 2014 13.94%
Sep 30, 2014 3.94%
Jun 30, 2014 12.05%
Mar 31, 2014 -10.73%
Dec 31, 2013 34.00%
Sep 30, 2013 -12.56%
Jun 30, 2013 20.25%
Mar 31, 2013 -17.35%
Dec 31, 2012 -112.18%
Sep 30, 2012 33.11%
Jun 30, 2012 -37.37%
Mar 31, 2012 -25.29%